ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.
The abstract highlights the new clinical data from Enzychem’s Phase 2 US clinical trial evaluating the effect of EC-18 on severe oral mucositis (SOM) development in chemoradiation-treated head and neck cancer patients. Dr. Christina Henson, a board-certified Radiation Oncologist and Residency Program Director for Radiation Oncology at the University of Oklahoma will present the following abstract. She was also the highest enrolling site’s principal investigator of the Phase 2 study.
The details of the presentation are as follows:
Title: Phase 2, Randomized, Double-Blind Trial of EC-18 versus Placebo to Mitigate the Development and Time Course of Oral Mucositis from Concomitant Chemoradiation for Head and Neck Cancer
Presenter: Christina Henson, M.D
Date: June 4th, 2022
Time: 1:15-4:15 PM (CDT)
About Enzychem Lifesciences
Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. For more information, please visit www.enzychem.com.
